OVID has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
OVID has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-01), the Trailing Annual Dividend Yield of Ovid Therapeutics is 0.00%.
The historical rank and industry rank for Ovid Therapeutics's Dividend Yield % or its related term are showing as below:
Ovid Therapeutics's Dividend Payout Ratio for the three months ended in Dec. 2023 was 0.00.
As of today (2024-05-01), the Forward Dividend Yield % of Ovid Therapeutics is 0.00%.
Ovid Therapeutics's Dividends per Share for the three months ended in Dec. 2023 was $0.00.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
The historical data trend for Ovid Therapeutics's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ovid Therapeutics Annual Data | |||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||||||
Dividend Yield % | Get a 7-Day Free Trial | - | - | - | - | - |
Ovid Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Dividend Yield % | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Ovid Therapeutics's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Ovid Therapeutics's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Ovid Therapeutics's Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Ovid Therapeutics (NAS:OVID) Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.
Thank you for viewing the detailed overview of Ovid Therapeutics's Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Jason Tardio | officer: Chief Commercial Officer | 1460 BROADWAY, NEW YORK NY 10036 |
Takeda Pharmaceuticals U.s.a., Inc. | 10 percent owner | ONE TAKEDA PARKWAY, DEERFIELD IL 60015 |
Kevin Joseph Fitzgerald | director | C/O OVID THERAPEUTICS INC., 1460 BROADWAY, SUITE 15044, NEW YORK NY 10036 |
Amit Rakhit | officer: CMO and PMO | C/O OVID THERAPEUTICS INC., 1460 BROADWAY, SUITE 15044, NEW YORK NY 10036 |
Robert Michael Poole | director | 200 W. HIGHLAND DR., #303, SEATTLE WA 98119 |
Jeffrey A Rona | officer: Chief Business Officer | 500 PLAZA DRIVE, SECAUCUS NJ 07094 |
Jeremy M Levin | director, 10 percent owner, officer: CEO | |
Takeda Pharmaceutical Co Ltd | 10 percent owner | 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668 |
Thomas Michael Perone | officer: SVP, General Counsel | 1460 BROADWAY, NEW YORK NY 10036 |
Karen Bernstein | director | C/O VITAE PHARMACEUTICLS, INC., 502 WEST OFFICE CENTER DRIVE, FORT WASHINGTON PA 19034 |
Millennium Pharmaceuticals Inc | 10 percent owner | 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
Douglas E Williams | director | C/O AMGEN INC, ONE AMGEN CENTER DR, THOUSAND OAKS CA 91320-1799 |
Ana Ward | officer: SVP and General Counsel | C/O OVID THERAPEUTICS INC., 1460 BROADWAY, SUITE 15044, NEW YORK NY 10036 |
Barbara Gayle Duncan | director | C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013 |
Timothy Daly | officer: VP, Finance & Corp. Controller | 20 KINGSBRIDGE ROAD, PISCATAWAY NJ 08854 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 06-29-2022
By GuruFocus Research • 11-06-2023
By GuruFocusNews GuruFocusNews • 06-09-2022
By sperokesalga sperokesalga • 05-01-2023
By sperokesalga sperokesalga • 02-28-2023
By sperokesalga sperokesalga • 05-05-2023
By Marketwired • 08-04-2023
By GuruFocusNews GuruFocusNews • 07-09-2022
By sperokesalga sperokesalga • 04-27-2023
By Marketwired • 09-26-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.